The development of a new Q-fever vaccine is a little closer to realisation. The blood of the inhabitants of Herpen that was sent to America for research purposes in 2015 was successfully analysed. Now, it is time for the next step.
Innatoss is developing this Q-fever vaccine, and, for the next phase, is looking for people who were vaccinated, or had chronic Q-fever and were treated for this 1 to 2 years ago. This blood is needed in order to compare the new vaccine to the one that is currently registered in Australia. By doing so, what is important in an immune response against Q-fever can be understood.
Financed by America
This research on the new Q-fever vaccine is financed by the American government, who feels that Q-fever is a big threat for soldiers that are sent to the Middle East. Even though there is a registered Q-fever vaccine in Australia, this is not used in America and Europe, because of its side effects.
Looking for volunteers
For the next phase of the research, Innatoss is looking for people who were vaccinated in 2011 during the campaign of the RVIM, and people who had chronic Q-fever and finished their treatment for this 1 to 2 years ago. Because this particular group is hard to reach (they are not part of groups, like Q-uestion), the company asks the media for help in order to find these people.
Volunteers that participate in the study are asked to have blood drawn for a maximum of six times during a period of two years. The blood is necessary to see whether the vaccine has the same immune response as the current vaccine.
The expectation is that Innatoss will have a clear picture about the effect of the vaccine halfway through 2018. After that, it will take another three years before the vaccine will be released.